[{"address1": "830 Winter Street", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "781 999 0232", "website": "https://www.q32bio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. The company is developing Bempikibart (ADX-914), a fully human anti\u0096interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase 2a clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. It is also discovering and developing the ADX-096, a C3d \u0096 CR1 fusion protein, and other earlier stage assets, including C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.", "fullTimeEmployees": 42, "companyOfficers": [{"maxAge": 1, "name": "Ms. Jodie Pope Morrison", "age": 48, "title": "CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 852632, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shelia M. Violette Ph.D.", "age": 63, "title": "Co-founder, Chief Scientific Officer & President of Research", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 619930, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jason A. Campagna M.D., Ph.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 680927, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lee H. Kalowski M.B.A.", "age": 43, "title": "CFO & President", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Saul W. Fink Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Appugliese J.D.", "title": "Senior VP & Head of People", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria  Marzilli M.P.H.", "title": "Executive Vice President of Corporate Strategy & Program Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathryn E. Golden M.B.A.", "title": "Head of Chemistry, Manufacturing & Controls", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.89, "open": 1.87, "dayLow": 1.7, "dayHigh": 1.94, "regularMarketPreviousClose": 1.89, "regularMarketOpen": 1.87, "regularMarketDayLow": 1.7, "regularMarketDayHigh": 1.94, "payoutRatio": 0.0, "forwardPE": -0.31902984, "volume": 159916, "regularMarketVolume": 159916, "averageVolume": 229700, "averageVolume10days": 106310, "averageDailyVolume10Day": 106310, "bid": 1.74, "ask": 1.78, "bidSize": 2, "askSize": 1, "marketCap": 20857896, "fiftyTwoWeekLow": 1.7, "fiftyTwoWeekHigh": 53.79, "fiftyDayAverage": 2.5869, "twoHundredDayAverage": 23.789625, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -38206080, "profitMargins": 0.0, "floatShares": 4728893, "sharesOutstanding": 12197600, "sharesShort": 1008620, "sharesShortPriorMonth": 1313826, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.08270001, "heldPercentInsiders": 0.08696, "heldPercentInstitutions": 0.86347, "shortRatio": 4.37, "impliedSharesOutstanding": 12197600, "bookValue": 0.465, "priceToBook": 3.6774194, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -47733000, "trailingEps": -6.58, "forwardEps": -5.36, "lastSplitFactor": "1:18", "lastSplitDate": 1711411200, "enterpriseToEbitda": 0.582, "52WeekChange": -0.905, "SandP52WeekChange": 0.06429911, "quoteType": "EQUITY", "currentPrice": 1.71, "targetHighPrice": 20.0, "targetLowPrice": 6.0, "targetMeanPrice": 13.66667, "targetMedianPrice": 15.0, "recommendationMean": 2.33333, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 77965000, "totalCashPerShare": 6.392, "ebitda": -65615000, "totalDebt": 18901000, "quickRatio": 4.769, "currentRatio": 4.973, "debtToEquity": 333.057, "returnOnAssets": -0.59278, "grossProfits": -48143000, "freeCashflow": -37946752, "operatingCashflow": -67715000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "QTTB", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1743204281, "regularMarketTime": 1743192000, "exchange": "NGM", "messageBoardId": "finmb_669405676", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "earningsTimestamp": 1741690743, "earningsTimestampStart": 1746621000, "earningsTimestampEnd": 1747053000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -6.58, "epsForward": -5.36, "fiftyDayAverageChange": -0.87689996, "fiftyDayAverageChangePercent": -0.33897713, "twoHundredDayAverageChange": -22.079624, "twoHundredDayAverageChangePercent": -0.9281199, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevExchange": "NGM", "exchangeTransferDate": "2025-03-24", "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1522243800000, "postMarketChangePercent": 5.26315, "postMarketPrice": 1.8, "postMarketChange": 0.0899999, "regularMarketChange": -0.17999995, "regularMarketDayRange": "1.7 - 1.94", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 229700, "fiftyTwoWeekLowChange": 0.00999999, "fiftyTwoWeekLowChangePercent": 0.005882347, "fiftyTwoWeekRange": "1.7 - 53.79", "fiftyTwoWeekHighChange": -52.08, "fiftyTwoWeekHighChangePercent": -0.96820974, "fiftyTwoWeekChangePercent": -90.5, "marketState": "CLOSED", "regularMarketChangePercent": -9.523807, "regularMarketPrice": 1.71, "shortName": "Q32 Bio Inc.", "longName": "Q32 Bio Inc.", "displayName": "Q32 Bio", "trailingPegRatio": null, "__fetch_time": "2025-03-29"}]